1998年首个核苷类似物药物拉米夫定推出之前，慢性乙肝病毒感染者可选的有效治疗途径一直都非常有限。
Effective treatment options for individuals with chronic hepatitis B infection were limited until 1998 when lamivudine, the first nucleoside analogue drug, was introduced.
目的探讨苦参碱和拉米夫定治疗活动性肝硬化的临床疗效。
Objective to investigate the clinical therapeutic effect of matrine and lamivudine on the active hepatocirrhosis.
结论拉米夫定治疗后il - 18水平下降，提示拉米夫定可调节免疫功能，减轻肝脏炎症细胞浸润。
Conclusion the decline of serum level of IL-18 showed lamivudine may regulate the function of immunity and alleviate soakage of inflammation cell in liver.
二代拉米夫定的长期应用可以有效地抑制病毒多聚酶突变频繁的HBV发生复制。
Long-term treatment with the second-generation nucleoside analogue lamivudine (lam) efficiently inhibits HBV replication with frequent viral polymerase mutations.
结论：临床应重视拉米夫定的不良反应，以确保用药安全。
CONCLUSION: Great importance should be attached to ADRs of lamivudine to ensure the safety of drug use in clinic.
目的研究乙型肝炎病毒感染对患者生存质量的影响及拉米夫定治疗后对患者生存质量的改善情况。
OBJECTIVE: To study the effect of HB viral infection on survival quality of the patients and improvement of patients survival quality after treatment with lamivudine.
她说，因为拉米夫定同另一种广泛用于HIV治疗的药物恩曲他滨是同种类型的，它的效果也受到恩替卡韦的抑制。
Because lamivudine is in the same category of HIV therapies as another widely used drug, emtricitabine, its effectiveness is also compromised by entecavir, she says.
结论拉米夫定治疗儿童慢性乙型肝炎是安全有效的药物之一。
Conclusion Lamivudine is a safe and effective medicine in treating children with chronic hepatitis B.
目的观察拉米夫定治疗儿童慢性乙型肝炎的临床疗效及对乙肝病毒标志物的影响。
Objective To observe the clinic effect of lamivudine in children with chronic hepatitis B and its influence of HBV markers.
目的确定乙型肝炎病毒（HBV）基因型在山东地区的分布及拉米夫定抗病毒疗效的影响。
Objective To ascertain the distribution of HBV genotypes in Shandong province and its relationship with the antiviral effect of lamivudine.
《国际肝病》：目前在中国，仍然在大量应用拉米夫定。那么，当患者停止治疗时，我们如何最大限度的降低复发风险？
Hepatology Digest: China still USES a lot of lamivudine. How can we minimize the risk of relapse when we take patients off therapy?
目的研究复方牛胎肝提取物联合拉米夫定对慢性乙型病毒性肝炎患者肝纤维化的影响。
Objective To study the effect of compound fetal bovine liver extract tablets in combination with lamivudine on hepatic fibrosis in patients with chronic hepatitis B.
结论对拉米夫定治疗6个月以上而没有达到病毒学完全应答的患者进行YMDD变异检测，有助于及时调整治疗方案。
Conclusion it would be helpful to adjust the therapeutic regimen by testing YMDD mutations in patients who receive lamivudine therapy more than 6 months without complete virologic response.
拉米夫定治疗乙型肝炎肝硬化失代偿期的临床观察。
Clinical Observation of Lamivudine for Decompensated Cirrhosis Resulting from Chronic Hepatitis b.
但我们也要记住，替诺福韦和拉米夫定也都会出现在母乳中，不过其含量非常低，可能不会有太大影响。
Remember also, the drugs tenofovir and lamivudine both appear in breast milk but in very low levels and probably have little effect.
结论：拉米夫定治疗慢性乙型肝炎，可以明显降低血清hbv - DNA及转氨酶水平，延缓肝组织纤维化的进展，减轻肝组织的炎症坏死。
Conclusion: Lamivudine treatment could decrease the HBV-DNA and transaminase level, and delay the progression of liver fibrosis and lighten inflammation and necrosis of liver.
目的：探讨乙肝病毒(HBV)基因型与拉米夫定疗效的关系。
Objective: To investigate the relationship between HBV genotypes and therapeutic effects of Lamivudine.
结论：交替使用轮拉米夫定、干扰素的序贯方法，有助病人忍受长期治疗并免于出现病毒株变异。
CONCLUSION: Sequential approach of alternate rounds of lamivudine or interferon may help patients to tolerate a prolonged schedule of therapy and protect them from emergence of viral strains.
结论：中药联合拉米夫定治疗慢性乙型肝炎能提高临床疗效，但是其作用机制有待进一步研究。
Conclusion: Chinese medicine with Lamivudine is effective in the treatment of chronic hepatitis B. its mechanisms are to be further investigated.
结论治疗前较高的ALT水平，较低的HBVDNA定量值及出现早期病毒学应答是影响拉米夫定治疗慢性乙型肝炎疗效的主要因素。
Conclusions the relatively high ALT level, low HBV DNA ration and early virus response are the major factors that affect the curative effect of lamivudine in treating chronic hepatitis B.
目的：探讨使用拉米夫定后产生不良反应的一般规律和特点。
Objective: To discuss the general rules and characteristics of adverse drug reactions (ADRS) of lamivudine.
目的观察拉米夫定联合氧化苦参碱对抗慢性乙型肝炎(乙肝)肝纤维化的临床疗效。
Objective To observe the clinical effect of both oxymatrine and lamivudine on hepatic fibrosis induced by chronic hepatitis b.
说明拉米夫定治疗不能阻断所有新生儿围产期的母婴传播。
Lamivudine therapy might not prevent perinatal transmission of HBV infection in every newborn.
结论：拉米夫定治疗慢性乙肝及乙肝病毒携带者安全有效。
Conclusion: Lamivudin is efficient and safe medicine in the treatment of CHB and HBV carrier.
目的对比研究同一慢性乙型肝炎患者拉米夫定治疗前及病情急性恶化后乙型肝炎病毒（HBV）株的结构基因组。
Objective To compare the structural genome variations of lamivudine resistant HBV strain from a patient with acute exacerbation after lamivudine therapy with pretretment HBV strain.
结论拉米夫定治疗慢性乙型重型肝炎，可缓解病情，改善肝功能，抑制HBV复制，但对病死率无显著影响。
ConclusionPreliminary data indicate that lamivudine therapy can significantly improve liver function and effectively inhibit HBV replication, but not to effect the fatality rates.
结果：拉米夫定不良反应临床表现多种多样，以肝炎病情加重为主。
RESULTS: The adverse drug reactions (ADRs) of lamivudine clinical manifestation to be many and varied, by hepatitis condition aggravation primarily.
结论：YMDD变异后停用拉米夫定的患者将冒很大风险，容易导致肝功能肝功能衰竭。
Conclusion: Patients who withhold lamivudine after YMDD mutation will run great risks, which may lead to hepatic failure.
预防性短期使用拉米夫定预防HBV再激活是有效及安全的。
It is effective and safe that preventing HBV reactivation by lamivudine in a short term.
目的研究拉米夫定停药后慢性乙型肝炎复发病例的临床特点和相关因素。
Objective To investigate the cases of chronic hepatitis B relapse after lamivudine withdrawal, and to find clinical characteristics and related factors to them.
应用推荐